Hemostasis Today

November, 2026
November 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Teresa Gerardi: KIT Inhibition with Avapritinib and Its Potential Impact on Mastocytosis-Related Osteoporosis
Nov 22, 2026, 12:41

Teresa Gerardi: KIT Inhibition with Avapritinib and Its Potential Impact on Mastocytosis-Related Osteoporosis

Teresa Gerardi, Hematology resident, shared a post on LinkedIn:

“Proud to share our work at the Swiss Oncology and Hematology Congress (SOHC) 2026!

Alongside my clinical work in hematology at Geneva University Hospitals (HUG), I am particularly interested in myeloproliferative neoplasms and mastocytosis, with a growing focus on clinical research and targeted therapies.

This year, I had the opportunity to present our poster:

‘Targeting the Clone to Target the Bone: Could KIT Inhibition Modify Mastocytosis Related Osteoporosis?’

Through a clinical case of indolent systemic mastocytosis treated with avapritinib, we explored whether targeting the KIT mutated mast cell clone could have an impact beyond disease burden, potentially influencing mastocytosis related bone disease.

Our findings highlight encouraging biological and molecular responses, while raising important questions about their long term clinical implications.

Connecting molecular mechanisms, targeted treatments, and meaningful patient outcomes is exactly the kind of research I am eager to pursue.

Grateful to my co authors and colleagues for their collaboration and support!”Teresa Gerardi: KIT Inhibition with Avapritinib and Its Potential Impact on Mastocytosis-Related Osteoporosis

Stay updated with Hemostasis Today.